参考文献/References:
[1] McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004.
[2] 葛均波,霍勇,杨杰孚,等.慢性心力衰竭"新四联"药物治疗临床决策路径专家共识[J].中国循环杂志,2022,37(8):769-781.
[3] Campbell DJ.Long-term neprilysin inhibition-implications for ARNIs[J].Nat Rev Cardiol,2017,14(3):171-186.
[4] Krittanawong C,Kitai T.Pharmacogenomics of angiotensin receptor/neprilysin inhibitor and its long-term side effects[J].Cardiovasc Ther,2017,35(4):e12272.
[5] Singh PK,Chen ZL,Ghosh D,et al.Increased plasma bradykinin level is associated with cognitive impairment in Alzheimer’s patients[J].Neurobiol Dis,2020,139:104833.
[6] Mizerska-Kowalska M,Bojarska-Junak A,Jakubowicz-Gil J,et al.Neutral endopeptidase (NEP) is differentially involved in biological activities and cell signaling of colon cancer cell lines derived from various stages of tumor development[J].Tumour Biol,2016,37(10):13355-13368.
[7] Kaplinsky E.Sacubitril/valsartan in heart failure:latest evidence and place in therapy[J].Ther Adv Chronic Dis,2016,7(6):278-290.
[8] Nalivaeva NN,Zhuravin IA,Turner AJ.Neprilysin expression and functions in development,ageing and disease[J].Mech Ageing Dev,2020,192:111363.
[9] Chen XY,Xue Y,Chen H,et al.The globus pallidus as a target for neuropeptides and endocannabinoids participating in central activities[J].Peptides,2020,124:170210.
[10] Fischer HS,Zernig G,Schuligoi R,et al.Alterations within the endogenous opioid system in mice with targeted deletion of the neutral endopeptidase (’enkephalinase’) gene[J].Regul Pept,2000,96(1-2):53-58.
[11] Campbell DJ,Krum H,Esler MD.Losartan increases bradykinin levels in hypertensive humans[J].Circulation,2005,111(3):315-320.
[12] Zou LB,Mouri A,Iwata N,et al.Inhibition of neprilysin by infusion of thiorphan into the hippocampus causes an accumulation of amyloid Beta and impairment of learning and memory[J].J Pharmacol Exp Ther,2006,317(1):334-340.
[13] Hanson LR,Hafez D,Svitak AL,et al.Intranasal phosphoramidon increases beta-amyloid levels in wild-type and NEP/NEP2-deficient mice[J].J Mol Neurosci,2011,43(3):424-427.
[14] Yasojima K,Akiyama H,McGeer EG,et al.Reduced neprilysin in high plaque areas of Alzheimer brain:a possible relationship to deficient degradation of beta-amyloid peptide[J].Neurosci Lett,2001,297(2):97-100.
[15] Zhang H,Liu D,Wang Y,et al.Meta-analysis of expression and function of neprilysin in Alzheimer’s disease[J].Neurosci Lett,2017,657:69-76.
[16] Chen GF,Xu TH,Yan Y,et al.Amyloid beta: structure,biology and structure-based therapeutic development[J].Acta Pharmacol Sin,2017,38(9):1205-1235.
[17] Hafez D,Huang JY,Huynh AM,et al.Neprilysin-2 is an important β-amyloid degrading enzyme[J]. Am J Pathol,2011,178(1):306-312.
[18] Iwata N,Higuchi M,Saido TC,et al.Metabolism of amyloid-beta peptide and Alzheimer’s disease[J].Pharmacol Ther,2005,108(2):129-148.
[19] Ji B,Wang Q,Xue Q,et al.The dual role of kinin/kinin receptors system in Alzheimer’s disease[J].Front Mol Neurosci,2019,12:234.
[20] Vodovar N,Paquet C,Mebazaa A,et al.Neprilysin,cardiovascular,and Alzheimer’s diseases: the therapeutic split? [J].Eur Heart J,2015,36(15):902-905.
[21] Pardridge WM.Drug transport across the blood-brain barrie[J].J Cereb Blood Flow Metab,2012,32(11):1959-1972.
[22] Bell RD,Zlokovic BV.Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease[J].Acta Neuropathol,2009,118(1):103-113.
[23] Clifford PM,Zarrabi S,Siu G,et al.Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons[J].Brain Res,2007,1142:223-236.
[24] Langenickel TH,Tsubouchi C,Ayalasomayajula S,et al.The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects[J].Br J Clin Pharmacol,2016,81(5):878-890.
[25] Schoenfeld HA,West T,Verghese PB,et al.The effect of angiotensin receptor neprilysin inhibitor,sacubitril/valsartan,on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey[J].Toxicol Appl Pharmacol,2017,323:53-65.
[26] de Jong LW,van der Hiele K,Veer IM,et al.Strongly reduced volumes of putamen and thalamus in Alzheimer’s disease: an MRI study[J].Brain,2008,131(Pt 12):3277-3285.
[27] González-Marrero I,Giménez-Llort L,Johanson CE,et al.Choroid plexus dysfunction impairs beta-amyloid clearance in a triple transgenic mouse model of Alzheimer’s disease[J].Front Cell Neurosci,2015,9:17.
[28] Balusu S,Brkic M,Libert C,et al.The choroid plexus-cerebrospinal fluid interface in Alzheimer’s disease: more than just a barrier[J].Neural Regen Res,2016,11(4):534-537.
[29] Hladky SB,Barrand MA.Elimination of substances from the brain parenchyma:efflux via perivascular pathways and via the blood-brain barrier[J].Fluids Barriers CNS,2018,15(1):30.
[30] de Vecchis R,Ariano C,di Biase G,et al.Cognitive performance of patients with chronic heart failure on sacubitril/valsartan:a?retrospective cohort study[J].Herz,2019,44(6):534-540.
[31] McMurray JJ,Packer M,Desai AS,et al.Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)[J].Eur J Heart Fail,2013,15(9):1062-1073.
[32] Krittanawong C,Kitai T.The head and the heart: potential long-term side effect of ARNI[J]. J Am Coll Cardiol,2017,69(14):1879-1880.
[33] Perlman A,Hirsh Raccah B,Matok I,et al.Cognition- and dementia-related adverse effects with sacubitril-valsartan:analysis of the FDA adverse event report system database[J].J Card Fail,2018,24(8):533-536.
[34] Hammadi SH,Hassan MA,Allam EA,et al.Effect of sacubitril/valsartan on cognitive impairment in colchicine-induced Alzheimer’s model in rats[J].Fundam Clin Pharmacol,2023,37(2):275-286.
[35]
McMurray JJV,Cannon JA, Quinn TJ,et al.Neprilysin inhibition does not affect cognitive function in patients with heart failure[R].Barcelona:ESC Congress,2022.
[36] Galo J,Celli D,Colombo R.Effect of sacubitril/valsartan on neurocognitive function: current status and future directions[J].Am J Cardiovasc Drugs,2021,21(3):267-270.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(8):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(8):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(8):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(8):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(8):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(8):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(8):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(8):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]潘东 罗勇.沙库巴曲缬沙坦在心力衰竭治疗中的研究进展[J].心血管病学进展,2020,(2):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
PAN DongLUO Yong.Sacubitril/valsartan in the Treatment of Heart Failure[J].Advances in Cardiovascular Diseases,2020,(8):114.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.003]
[12]费美莹 姜东炬.心力衰竭药物沙库巴曲缬沙坦的研究进展[J].心血管病学进展,2020,(2):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
FEI Meiying J IANG Dongju.Heart Failure Drug Sacubitril Valsartan[J].Advances in Cardiovascular Diseases,2020,(8):122.[doi:10.16806/j.cnki.issn.1004-3934.2020.02.005]
[13]程家元 殷跃辉.沙库巴曲缬沙坦在心血管疾病中的临床应用与展望[J].心血管病学进展,2020,(9):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]
CHENG Jiayuan YIN Yuehui.Clinical Application and Prospect of Sacubitril Valsartan in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2020,(8):914.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.007]